ARYx shuts up shop as it waits out SPA response from FDA
This article was originally published in Scrip
ARYx Therapeutics has failed to secure critical financing to enable it to continue operations and has shut up shop, blaming the US FDA for its delay in responding to ARYx' September SPA submission for naronapride. "Due to this delay and the lack of clarity as to the path forward for the development of naronapride, ARYx could not obtain the financing it expected to close in November", said the US firm.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.